UBS
Chelsea Therapeutics (Nasdaq: CHTP) 76.5% LOWER; announced top-line results from Study 302, the first of two Phase III trials of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension did not show statistically significant improvement versus placebo. Click here for the full report.
Leading Brands, Inc. (Nasdaq: LBIX) 37.9% HIGHER; reports Q2 EPS of $0.04, compared to a loss of $0.01 in the same quarter last year. Revenue for the quarter was $6.62 million, versus $5.89 million in Q208.
CombinatoRx, Incorporated (NASDAQ: CRXX) 17.9% HIGHER; today announced that the U.S. FDA in a joint meeting of its Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management Advisory Committee heard presentations and public testimony and discussed the New Drug Application submitted by Neuromed for EXALGOTM (hydromorphone HCl extended release) tablets, seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients ...
Uroplasty, Inc. (Amex: UPI) 46.4% HIGHER; today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System. The Urgent PC System is a proprietary, minimally invasive percutaneous tibial nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder.
Amedisys, Inc. (NASDAQ: AMED) 26.2% LOWER; today announced that it has acquired a hospice business with nine locations in South Carolina and one location in Mississippi. This acquisition, which represents Amedisys' entry into the hospice business in both South Carolina and Mississippi, will allow Amedisys to provide coverage to the entire state of South Carolina and to 17 counties in Mississippi. The business operates as Winyah Community Hospice Care in South Carolina and Allcare Hospice in Mississippi. The agencies had annualized revenue of approximately $17 million, but are ...
UBS upgrades Helicos BioSciences (Nasdaq: HLCS) from ...
